Apoptosis in (pre-) malignant lesions in the gastro-intestinal tract by Woude, Christien Janneke van der
  
 University of Groningen
Apoptosis in (pre-) malignant lesions in the gastro-intestinal tract
Woude, Christien Janneke van der
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2004
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Woude, C. J. V. D. (2004). Apoptosis in (pre-) malignant lesions in the gastro-intestinal tract. Groningen:
s.n.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
7CHAPTER 2
CHRONIC INFLAMMATION, APOPTOSIS AND 
(PRE-)MALIGNANT LESIONS IN THE 
GASTRO-INTESTINAL TRACT
C.J. van der Woude , J.H. Kleibeuker , P.L.M. Jansen , H. Moshage 
Adapted from Apoptosis 2004;9:123-130. 
81. NF-KB, INOS AND COX-2 EXPRESSION IN BARRETT’S ESOPHAGUS
Barrett’s esophagus (BE) is a typical pre-malignant condition of the esophagus. 
Normal epithelium is replaced by columnar epithelium and eventually this can evolve 
to adenocarcinoma1-3.
iNOS was reported to be induced in BE and BE associated carcinoma4-6. COX-2 
expression in BE is induced in both pre-cancerous and cancerous lesions. This could 
have implications for chemopreventive therapy. Although data are limited, selective 
inhibition of COX-2 in esophageal adenocarcinoma cells suppresses growth and 
induces apoptosis7-9. It was demonstrated that selective and non-selective COX-2 
inhibitors can inhibit inflammation, COX-2 activity, and development of 
adenocarcinoma induced by reflux10. On the other hand, in a retrospective trial 
among patients with BE, no difference in cancer risk in BE was found in the presence 
or absence of COX-inhibitors of the NSAID-family11. Finally, one report observed no 
COX-2 expression in dysplastic lesions in BE12.
In summary:  iNOS is induced in BE. Due to the scarcity of investigations, it is not 
clear what the exact consequences of iNOS in BE epithelium are with respect to 
survival and apoptosis. The use of iNOS inhibitors as chemopreventive intervention 
in BE has not been reported yet. The data on COX-2 expression and 
chemoprevention in BE are conflicting. No studies report on NF-kB activation in BE.
2. APOPTOSIS AND APOPTOSIS-RELATED PROTEINS IN BARRETT’S ESOPHAGUS
Apoptosis measured by counting apoptotic cells in different stages of BE was found 
to be increased in BE compared to normal fundus epithelium, whereas apoptosis 
determined by the TUNEL assay in BE was almost absent13,14. In BE, with or without 
dysplasia or carcinoma, decreased Fas expression has been reported15. This 
suggests a protective mechanism against apoptosis in BE and BE-associated 
adenocarcinoma. In addition to gastric acid in reflux esophagitis there is also reflux of 
bile in BE. Bile acids have been shown to activate Fas, inducing apoptosis in liver 
cells. The decreased expression of Fas may be an adaptation of epithelium against 
exposure to pro-apoptotic bile acids resulting in decreased sensitivity to apoptosis. 
Furthermore, bile acids have been shown to promote survival of cholangiocyte cell 
lines by activating the Epidermal Growth Factor (EGF) receptor16. If confirmed, this is 
9an example of an adaptation to inflammatory stress, resulting in an anti-apoptotic 
phenotype and predisposing to cancer. Reports on the expression of Bax in BE 
demonstrated a positive association between progression to adenocarcinoma and 
Bax expression17. Increased Bax expression alone in these cells may not be pro-
apoptotic perse. Only in response to an apoptotic trigger does Bax translocate from 
cytoplasm into mitochondrial membranes forming pores. In contrast, anti-apoptotic 
Bcl-2-family members are constitutively located in intracellular membranes including 
mitochondria, and therefore increased expression of these Bcl-2 members directly 
contribute to a more apoptosis-resistant phenotype. Reports on Bcl-2 expression in 
the neoplastic transformation to adenocarcinoma are scarce. Some studies showed 
an increased expression of Bcl-2 in neoplastic transformation, but others failed to 
demonstrate Bcl-2 expression at all in the epithelium of Barrett’s esophagus18-20. In 
contrast, expression of the anti-apoptotic Bcl-2 family member Bcl-xl increased in the 
sequence towards adenocarcinoma21 and this increase may compensate for the 
observed increase in Bax expression.
In summary: There are hardly any reports on apoptosis in BE. Distinct changes in the 
expression of Bcl-2 family members occur, but the consequences for the resistance 
against apoptosis are not clear.
3. NF-KB, INOS AND COX-2 EXPRESSION IN PRE-MALIGNANT AND MALIGNANT CONDITIONS 
IN THE STOMACH
According to the Lauren classification22, gastric adenocarcinomas can be divided into 
those of the diffuse and those of the intestinal type. Atrophic gastritis and intestinal 
metaplasia can eventually result in the development of pre-malignant and malignant 
lesions in intestinal type cancer23. It is well accepted that Helicobacter pylori-
associated gastritis is causally linked to both types of gastric cancer24-26.
Compared to normal gastric antral mucosa, NF-kB in Helicobacter pylori (Hp) gastritis 
is activated and translocated to the nuclei of epithelial cells and its expression 
correlates with the activity of gastritis3,27-30. NF-kB is not only activated in epithelial 
cells but also in endothelial cells, macrophages and B lymphocytes in the lamina 
propria. Several studies have demonstrated the activation of NF-kB by Helicobacter 
pylori in human gastric cancer cell lines and in vivo activation of NF-kB was 
demonstrated in intestinal type gastric carcinoma31,32. In the latter report a correlation 
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was found between NF-kB activity and clinicopathological features of the carcinoma. 
iNOS is induced in the gastric epithelium of patients with Helicobacter pylori-induced 
gastritis33,34 and also in epithelium of intestinal metaplasia35,36. Reports on the 
expression of iNOS in pre-malignant and malignant lesions showed an increased 
expression of iNOS37-42. Furthermore, in these studies, expression of iNOS correlates 
with tumor invasiveness, metastatic potential and a worse prognosis. A relationship 
between NF-kB activity and iNOS expression in Helicobacter pylori associated 
gastritis of humans has been demonstrated43,44. In these studies inhibition of NF-kB 
prevented iNOS expression and NO production. The authors suggested that iNOS 
inhibition was restricted to epithelial cells and did not occur in inflammatory cells of 
the lamina propria. Most studies report induction of COX-2 expression in Helicobacter 
pylori gastritis45,46,57. The localisation of COX-2 expression remains controversial: 
some studies showed COX-2 expression in both epithelial cells and lamina propria 
immune cells whereas other studies showed only expression in lamina propria 
immune cells. In addition, COX-2 expression has been demonstrated in epithelium of 
gastic atrophy and intestinal metaplasia and in both diffuse and intestinal type gastric 
adenocarcinoma47,48, no difference in COX-2 expression between diffuse and 
intestinal type gastric carcinoma was observed and not all tumor cells were positive 
for COX-249. Inhibition of NF-kB resulted in inhibition of COX-2 expression and 
inhibition of proliferation of gastric cancer cells50.
In summary: NF-kB, iNOS and COX-2 are induced in Hp-gastritis, intestinal 
metaplasia, dysplasia and adenocarcinoma of the stomach. The localisation and 
degree of expression varies between studies. NF-kB activation is involved in the 
expression of iNOS, COX-2 and cell proliferation. Some data suggest that inhibition 
of NF-kB activation or NF-kB-regulated genes may sensitize gastric cancer cells to 
apoptosis or inhibit their proliferation.
4. APOPTOSIS AND APOPTOSIS-RELATED PROTEINS IN PRE-MALIGNANT AND MALIGNANT 
CONDITIONS IN THE STOMACH
Gastric intestinal metaplasia is associated with increased apoptosis compared to 
normal gastric mucosa51.  Increased apoptosis, determined using the TUNEL assay, 
was demonstrated in intestinal type gastric carcinomas but other studies failed to 
confirm this finding. Since the TUNEL assay is prone to artefacts, other ways of 
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determining apoptosis should clarify this apparent discrepancy52-54. In one study 
activated caspase-3 was not detected in gastric cancer cells nor in the gastric 
mucosa surrounding the gastric cancer whereas in normal gastric mucosa activated 
caspase 3 expression was detected. This suggests that inhibition of apoptosis, as 
indicated by the lack of caspase-3 activation, is involved in the transformation to 
gastric carcinoma55. In normal gastric mucosa Fas expression is hardly detectable in 
epithelial cells. Fas expression increases in gastric atrophy and intestinal metaplasia 
and is detectable in all cases with dysplasia56. Vollmers et al reported Fas expression 
in the diffuse type carcinoma but not in the intestinal type carcinoma57, whereas we 
observed exactly the opposite result58. Another group reported high expression of 
Fas in gastric cancer cells and reduced Fas expression with the advancement of the 
carcinoma59. The increased Fas expression on malignant cells compared to normal 
gastric epithelium is difficult to explain. It remains to be determined whether the 
increased Fas expression really results in increased sensitivity to apoptosis. Possibly, 
increased Bcl-2 expression may counteract the increased Fas expression in terms of 
sensitivity to apoptosis: in normal gastric mucosa Bcl-2 expression is confined to only 
a few regenerating epithelial cells of the mucous neck region. Bcl-2 expression is 
increased in chronic gastritis, intestinal metaplasia and dysplasia60-64. Kyokane et al 
demonstrated Bcl-2 expression in early gastric cancer of the elevated type. This 
elevated type probably resembles adenomatous polyps in the colon65. Others 
demonstrated Bcl-2 expression in tumor cells of both intestinal type carcinoma as 
well as diffuse type gastric carcinoma, but mostly in a small percentage of the tumor 
cells66,67. However, the expression of Bcl-2 seems to be higher in intestinal type 
gastric cancer compared to diffuse type cancer68,69,75,76. Bax expression is reported in 
both intestinal and diffuse type carcinomas but seems to be decreased in comparison 
to the surrounding non-tumorous tissue, favouring an anti-apoptotic phenotype in 
gastric cancers70,83.
In summary: Apoptosis as determined by the expression of activated caspase-3 is 
reduced in gastric cancer compared to normal gastric mucosa. Reports on apoptosis 
using the TUNEL assay are conflicting. Expression of Fas and Bcl-2 proteins are 
increased in intestinal metaplasia, dysplasia and adenocarcinoma compared to the 
normal gastric mucosa, whereas Bax expression is reduced in gastric cancer cells. 
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5. NF-KB, INOS AND COX-2 EXPRESSION IN INFLAMMATORY BOWEL DISEASES
NF-kB activity varies in inflammatory bowel diseases (IBD). NF-kB activation has 
been observed in macrophages in the lamina proptria and in epithelial cells71,72. IL-
10, sulphasalazine and immunosuppressive drugs have been reported to inhibit NF-
kB activity in the mucosa of patients with Crohn’s disease and ulcerative colitis73-76.
iNOS is clearly expressed in epithelial cells of the inflamed gut77-79. The expression of 
COX-2 in surface epithelial cells and in lamina propria immune cells in areas of 
inflammation in Crohn’s colitis and ulcerative colitis is strongly induced80,81. COX-2 
overexpression has been described in sporadic colonic neoplasia and in colitis-
associated neoplasia but its exact role in neoplastic transformation is not yet clear. 
One group reported COX-2 overexpression in ulcerative colitis associated neoplasia 
and in this study the increase in COX-2 expression could not be explained by 
inflammatory activity alone82. However, in this report the expression of COX-2 in 
adenocarcinoma in longstanding colitis was not as uniform as in the dysplastic 
regions.
In summary: Only a limited amount of data concerning NF-kB activation and COX-2 
and iNOS expression in IBD-related carcinogenesis has been published. Although 
these proteins are induced in IBD, their role in oncogenesis is not known. 
6. APOPTOSIS AND APOPTOSIS-RELATED PROTEINS IN INFLAMMATORY BOWEL DISEASES
In normal intestinal epithelium apoptosis is observed in the crypt and at the luminal 
surface83. Bcl-2 is expressed in the bases of crypts, whereas epithelial cells on the 
luminal surface express less Bcl-284,85. Bax, Bcl-xl and Bak expression are confined 
to areas of colonic epithelial cells of the luminal surface86,106. There is a higher 
expression of Bak in the left colon compared to the right colon87. Fas is strongly 
expressed in all epithelial cells of the normal colon throughout the crypt88. In 
ulcerative colitis, apoptotic colonocytes are increased in number throughout the 
crypt89. In the same report Fas expression in the intestinal epithelium of ulcerative 
colitis patients was comparable to that of normal epithelial cells. Another report 
confirmed this90. In both reports Fas ligand was highly expressed compared to 
normal colonic epithelium. The reports on expression of apoptosis-related proteins in 
the epithelium of patients with ulcerative colitis and Crohn’s colitis are limited. In 
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active colitis, no change in Bcl-2 expression compared to normal colonic epithelium 
was observed96. Bcl-2 overexpression was observed in ulcerative colitis-associated 
neoplasia91. Compared to adenomas in areas involved in ulcerative colitis, Bcl-2 
expression in ulcerative colitis-associated dysplastic lesions is less frequent92. The 
expression of Bcl-2 in ulcerative-colitis-associated colorectal cancer is significantly 
lower compared to that in sporadic colorectal cancer93. Another report failed to 
demonstrate a significant difference in Bcl-2 expression between ulcerative colitis 
associated neoplasia and sporadic adenocarcinomas, although this study revealed 
less apoptosis in the ulcerative colitis associated neoplasia compared to sporadic 
adenocarcinomas94. Bax expression is reduced in ulcerative colitis compared to 
normal colonic mucosa95. Other reports on expression of apoptosis-related proteins 
in IBD are mainly focussed on lamina propria T cells.
In summary: Reports on apoptosis in IBD and associated neoplasia are limited. 
Conflicting data exist on the expression of Bcl-2 in colitis-associated neoplasia 
compared to sporadic carcinoma. Little is known about the expression in epithelium 
of other apoptosis-related proteins in the sequence from colitis to carcinoma.
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